Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors
Authors:
- Barbara MandrianiBMBarbara Mandriani
- Eleonora PellèEPEleonora Pellè
- Francesco MannavolaFMFrancesco Mannavola
- Antonio PalazzoAPAntonio Palazzo
- Renè Massimiliano MarsanoRMRenè Massimiliano Marsano
- Giuseppe IngravalloGiuseppe Ingravallo
- Gerardo CazzatoGerardo Cazzato
- Maria Cecilia RamelloMRMaria Cecilia Ramello
- Camillo PortaCPCamillo Porta
- Jonathan StrosbergJonathan Strosberg
- Daniel Abate-DagaDADaniel Abate-Daga
- Mauro CivesMCMauro Cives
Open Access
- 28 June 2022
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 10 (6) , e004854
Abstract
Background Neuroendocrine tumors (NETs) overexpress somatostatin receptors (SSTRs). Methods We developed a second-generation, ligand-based, anti-SSTR chimeric antigen receptor (CAR) incorporating the somatostatin analog octreotide in its extracellular moiety. Results Anti-SSTR CAR T cells exerted antitumor activity against SSTR+NET cell linesin vitro. The killing activity was highly specific, as demonstrated by the lack of CAR T cell reactivity against NET cells engineered to express mutated variants of SSTR2/5 by CRISPR/Cas9. When adoptively transferred in NSG mice, anti-SSTR CAR T cells induced significant antitumor activity against human NET xenografts. Although anti-SSTR CAR T cells could recognize the murine SSTRs as shown by their killing ability against murine NET cells, no obvious deleterious effects on SSTR-expressing organs such as the brain or the pancreas were observed in mice. Conclusions Taken together, our results establish anti-SSTR CAR T cells as a potential candidate for early phase clinical investigations in patients with NETs. More broadly, the demonstration that a known peptide drug can direct CAR T cell targeting may streamline the potential utility of multiple peptide motifs and provide a blueprint for therapeutic applications in a variety of cancers.Keywords
This publication has 50 references indexed in Scilit:
- Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse modelSurgery, 2012
- A human memory T cell subset with stem cell–like propertiesNature Medicine, 2011
- Improvement of drug-like properties of peptides: the somatostatin paradigmExpert Opinion on Drug Discovery, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study GroupJournal of Clinical Oncology, 2009
- Cloning of the Mouse SSTR5 GeneJournal of Surgical Research, 1998
- OctreotideNew England Journal of Medicine, 1996
- Is non-isotopic in situ hybridization finally coming of age?Nature, 1990
- Inferences about the conformation of somatostatin at a biologic receptor based on NMR studiesBioorganic Chemistry, 1978
- D-Trp8-somatostatin: An analog of somatostatin more potent than the native moleculeBiochemical and Biophysical Research Communications, 1975